Dry Macular Degeneration Risk and Your Genetics

What is dry macular degeneration risk?

Dry age-related macular degeneration (dry AMD) is the most common form of macular degeneration, accounting for roughly 80–85% of all AMD cases. It is defined by the gradual accumulation of drusen — small protein and lipid deposits beneath the retinal pigment epithelium (RPE) — followed by progressive thinning and loss of RPE cells in the central macula. Over time, this process can advance to geographic atrophy (GA), a stage marked by irreversible loss of photoreceptors that permanently reduces the sharp central vision needed for reading and face recognition. Genetics is one of several factors that shape population-level propensity; lifestyle choices and proactive monitoring meaningfully influence whether and how quickly the condition progresses.

Research base: Robust.

The genetics behind dry macular degeneration risk

Dry AMD has one of the strongest hereditary signatures of any common eye condition. Twin studies have estimated heritability at 45–70%, and genome-wide association studies have identified dozens of contributing loci. The genes in this trait reflect two major biological themes: complement-mediated chronic inflammation and extracellular matrix remodeling at the RPE–choroid interface.

Complement pathway genes

CFH encodes complement factor H, a circulating inhibitor of the alternative complement pathway that protects retinal tissue from runaway inflammatory activation. The CFH Y402H variant is the single most replicated genetic signal in all of AMD genetics, present in both dry and wet forms. In the macula, where complement activity is poorly regulated compared to other tissues, CFH variants shift the balance toward sustained low-grade inflammation — the environment in which drusen accumulate.

C3 sits at the convergence point of all three complement activation pathways. C3 cleavage products are deposited within drusen and in the sub-RPE space. Variants in C3 alter activation kinetics in ways that promote chronic macular inflammation.

C9 is the terminal complement component that assembles the membrane attack complex. C9 protein has been detected in drusen isolates, consistent with a role in localized complement-driven tissue injury at the RPE.

CFI encodes complement factor I, a serine protease that degrades C3b and C4b to limit complement amplification. Reduced CFI function prolongs complement activation in the sub-RPE space.

Drusen composition and Bruch's membrane ECM

Drusen are not inert deposits — they are complex structures containing lipids, complement proteins, clusterin-family proteins, and collagen fragments. The novel genes in this trait illuminate the ECM side of dry AMD biology.

CLUL1 (Clusterin-like 1) is a retina-expressed member of the clusterin protein family. The related protein CLU (clusterin) is a well-characterized component of drusen, found in sub-RPE deposits across multiple post-mortem AMD studies. CLUL1 shares structural homology with CLU and is expressed in retinal tissue, making it a compelling candidate for the drusen proteome story. Clusterin-family proteins appear to serve as molecular chaperones that modulate aggregation of misfolded proteins — a function highly relevant to the protein-rich environment of forming drusen.

COL10A1 encodes collagen type X alpha 1, a short-chain collagen most studied in hypertrophic cartilage. Bruch's membrane — the five-layered extracellular matrix sheet separating the RPE from the choriocapillaris — undergoes characteristic thickening and compositional changes in aging and AMD. As Bruch's membrane becomes less permeable, the transport of nutrients and metabolic waste products between the RPE and choroidal blood supply is impaired, accelerating drusen formation. COL10A1 variants may influence the collagen composition of this interface, contributing to the barrier dysfunction that sets the stage for geographic atrophy.

FAM8A1 (Family with sequence similarity 8 member A1) is an emerging GWAS-identified locus that has appeared in large-scale AMD association analyses. Its precise mechanistic role remains under active investigation; it is included here as a replicated statistical signal near established AMD biology rather than a characterized functional gene.

Lipid metabolism genes

APOE encodes apolipoprotein E, the major apoprotein of chylomicrons and a critical regulator of lipid metabolism. In the retina, APOE is expressed by Müller glia and RPE cells, where it facilitates cholesterol trafficking. The RPE's high metabolic demand for lipid handling — including daily phagocytosis of photoreceptor outer segments — makes APOE-mediated cholesterol efflux particularly important. APOE isoforms (E2/E3/E4) influence drusen lipid content and RPE cholesterol accumulation, with the E4 allele associated with altered AMD risk profiles.

CETP encodes cholesteryl ester transfer protein, which mediates the exchange of cholesterol esters and triglycerides between lipoprotein particles. CETP activity affects HDL composition and cholesterol efflux pathways that have relevance to retinal lipid homeostasis.

Choroidal ECM

ARMS2 encodes a small secreted protein specific to primates, with highest expression in the choriocapillaris region. ARMS2 protein localizes to the choroidal extracellular matrix, and variants in ARMS2 are among the most strongly and specifically associated signals in AMD genetics across both dry and wet subtypes. The ARMS2 A69S variant is typically measured together with nearby HTRA1 variants due to strong linkage disequilibrium, making regional ECM integrity a recurring theme.

What the research says

The large-scale genetic architecture of dry macular degeneration risk has been characterized across diverse populations. A landmark 2024 study examined the genetic architecture of 2,068 traits in the VA Million Veteran Program, one of the largest and most ancestrally diverse biobanks assembled for genomic research. This work confirmed the broad replicability of AMD-associated loci across ancestries and demonstrated that complement pathway variants and ECM-related signals each contribute independent effects to AMD susceptibility (Verma A et al., 2024, Science, PMID 39024449).

~80–85% of all AMD cases are the dry (non-neovascular) form. Dry AMD is the leading cause of legal blindness in adults over 65 in high-income countries.

The AREDS and AREDS2 clinical trials — conducted across thousands of participants with intermediate to advanced dry AMD — remain the strongest source of evidence for a modifiable intervention. AREDS2 established that a specific combination of vitamins C and E, lutein, zeaxanthin, zinc, and copper reduces the risk of progression from intermediate dry AMD to advanced AMD by approximately 25% over five years. This is the only FDA-evidence-supported nutritional intervention for dry AMD progression.

~25% reduction in risk of progression to advanced AMD with the AREDS2 supplement formula among people with intermediate dry AMD — the most robust nutritional intervention in ophthalmology.

Approximately 10–15% of dry AMD cases eventually convert to wet (neovascular) AMD, a more rapidly progressing form driven by VEGF-mediated abnormal blood vessel growth beneath the retina. The chronic complement-mediated inflammation that drives drusen accumulation in dry AMD is thought to create conditions permissive for this conversion. Monitoring for the signs of wet conversion — sudden changes in central vision distortion — is therefore a core part of dry AMD management regardless of genetic profile.

How dry macular degeneration risk affects you

Your genetic result for dry macular degeneration risk reflects where you fall in a population-level distribution of propensity — not a certainty about your future vision. Most people who carry elevated-risk variants do not develop advanced dry AMD, and many people without high-risk variants do develop the condition. Age is the dominant risk factor overall; AMD is rare before 55 and increases steeply in prevalence after 65.

What genetics can meaningfully inform:

Motivation for screening. Knowing you carry a higher population-level propensity for dry AMD is a rational prompt to establish a relationship with an ophthalmologist and begin baseline imaging (optical coherence tomography, fundus photography) earlier than the general population might.
Lifestyle calibration. Smoking is the single most important modifiable risk factor for AMD progression — roughly doubling risk independent of genetics. UV light exposure, diet quality, and cardiovascular health also carry evidence-based associations with AMD risk and progression rate.
Supplement consideration. If early drusen are detected on examination, the AREDS2 formula is a conversation to have with your eye care provider — it is among the most evidence-supported nutritional interventions in ophthalmology.

Important framing: the complement genes in this trait (CFH, C3, C9, CFI) reflect population-level variation in immune regulation in the macula. They do not determine your trajectory. The ECM genes (CLUL1, COL10A1) and lipid genes (APOE, CETP) represent additional biological dimensions that shape the drusen microenvironment — each a partial contributor, not a singular cause.

Working with your dry macular degeneration risk result

If your result indicates elevated genetic propensity for dry macular degeneration, the most productive framing is: genetics as motivation, not fate.

Proactive monitoring steps:

Schedule a comprehensive dilated eye exam with an ophthalmologist, and discuss your genetic result as context for screening frequency.
Ask about optical coherence tomography (OCT) imaging, which can detect early sub-RPE changes before symptoms appear.
Use an Amsler grid — a simple paper grid available from any eye care provider — for weekly home monitoring of central vision distortion. Any new distortion warrants prompt evaluation for wet AMD conversion.

Lifestyle modifications with evidence support:

Do not smoke, and avoid secondhand smoke. Smoking is the most robustly established modifiable risk factor for AMD across all genetic risk strata.
Eat a diet rich in leafy greens and fatty fish. Lutein and zeaxanthin (found in kale, spinach, eggs) concentrate in the macula; omega-3 fatty acids are associated with lower AMD prevalence in observational studies.
Protect eyes from high-intensity UV light with wraparound sunglasses that block UV-A and UV-B.
Manage cardiovascular risk factors. Hypertension and dyslipidemia have been associated with AMD in large observational studies.

AREDS2 supplement discussion: The AREDS2 formula (500 mg vitamin C, 400 IU vitamin E, 10 mg lutein, 2 mg zeaxanthin, 80 mg zinc, 2 mg copper) is specifically indicated for people with documented intermediate dry AMD or advanced AMD in one eye. It is not currently recommended as a preventive measure for people without clinical AMD findings. Whether your genetic profile changes this calculus is a conversation for your ophthalmologist.

If your result is lower propensity: Lower genetic propensity does not eliminate risk. Age-related factors and environmental exposures contribute independently. Routine eye care remains appropriate for all adults over 50.

Dry macular degeneration biology overlaps with several related ExomeDNA trait categories:

Wet macular degeneration risk — the neovascular form of AMD shares many of the same complement and ARMS2 genetic signals but involves VEGF-driven abnormal vessel growth as the critical progression step. [See: wet-macular-degeneration-risk]
Macular degeneration risk — the broader AMD trait that aggregates dry and wet signals together. [See: macular-degeneration-risk]
Glaucoma risk — a distinct condition of optic nerve degeneration with some shared GWAS architecture in eye-related ECM and pressure-regulation genes. [See: glaucoma-risk]
Inflammatory response — complement pathway variation (CFH, C3, CFI) connects AMD genetics to broader systemic immune regulation phenotypes. [See: inflammatory-response]
Vitamin D levels — vitamin D receptors are expressed in retinal tissue and vitamin D deficiency has been examined as a modifier of AMD risk in observational studies. [See: vitamin-d-levels]
CFH gene page — complement factor H is the foundational genetic signal across AMD subtypes. [See

Frequently asked questions

Q: Is dry AMD genetic or environmental? A: Both. Heritability estimates from twin studies place genetics at 45–70% of the variance in AMD risk, making it one of the most heritable common age-related conditions. But that means 30–55% of variance is attributable to non-genetic factors — including smoking (the largest modifiable risk factor), diet, UV exposure, and cardiovascular health. Your genetic result reflects the inherited component of your population-level propensity; the modifiable factors remain meaningfully within your influence.

Q: Which genes matter most for dry AMD specifically? A: CFH and ARMS2 carry the largest effect sizes in AMD genetics overall and appear in both dry and wet AMD. For dry AMD specifically, the drusen-biology genes — including CLUL1 (a clusterin-family protein expressed in retinal tissue) and COL10A1 (a collagen with relevance to Bruch's membrane composition) — represent the more differentiated dry AMD molecular story. C3, C9, CFI, APOE, and CETP each contribute through complement activation and lipid metabolism pathways.

Q: If I have high genetic risk, will I definitely lose central vision? A: No. Genetic propensity reflects population-level patterns, not individual destiny. Many people with high-risk variants never develop significant AMD, and many people without high-risk variants do develop it — because age, smoking, diet, and other factors contribute independently. Regular monitoring and established lifestyle modifications meaningfully affect progression rates even among those with elevated genetic propensity.

Q: Should I take AREDS2 supplements because of my genetic result? A: The AREDS2 formula has the strongest evidence for people with documented intermediate dry AMD or advanced AMD in one eye — confirmed on clinical examination. Whether genetic propensity alone, in the absence of clinical findings, changes the supplement calculus is a question to discuss with your ophthalmologist. Taking AREDS2 supplements without clinical AMD findings confirmed on examination and without medical supervision is not recommended based on current evidence.

Q: What is the difference between dry and wet AMD, and can one turn into the other? A: Dry AMD involves the gradual accumulation of drusen and progressive RPE thinning, advancing in its most severe form to geographic atrophy. Wet (neovascular) AMD involves abnormal blood vessel growth beneath the retina, which can leak and cause more rapid vision loss. Approximately 10–15% of dry AMD cases eventually convert to wet AMD. The chronic complement-mediated inflammation driving dry AMD creates conditions that can promote VEGF-driven vessel growth. Monitoring for conversion — any sudden increase in central distortion — is an important part of dry AMD management.

Q: How often should I get eye exams if I have elevated dry AMD genetic risk? A: General guidance for adults over 60 is a comprehensive dilated eye exam every 1–2 years. If additional risk factors are present — elevated genetic propensity, family history of AMD, early drusen on prior examination, or active smoking — discussing a more frequent monitoring schedule with your ophthalmologist is reasonable. Between exams, weekly Amsler grid self-monitoring can help detect early signs of wet conversion.

References

Verma A et al. (2024). Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. Science. PMID: 39024449. DOI: 10.1126/science.adj1182

Data sources: Genetic association data sourced from large-scale genome-wide association studies including the VA Million Veteran Program. Gene functional annotations informed by NCBI Gene database entries for C3, APOE, ARMS2, CLUL1, COL10A1, CFH, CFI, C9, CETP, and FAM8A1.

By the ExomeDNA Research Team

This page contains general information only. For personal health decisions, consult a qualified clinician.

ExomeDNA genetic results are for wellness and educational purposes only. Consult a clinician for personalized health guidance. Genetic results do not substitute for professional clinical evaluation.

Browse all traits →